Rx drug word-of-mouth occurs largely offline: study

Share this article:

Less than 10% of drug-related word-of-mouth takes place online, compared with 74% happening in person, according to a Keller Fay Group report. 

The statistic should be an eye-opener for marketers obsessing over emerging digital media and blogs, explained Ed Keller, CEO, Keller Fay Group. “For some brands, it's important to facilitate talk online,” said Keller, but reaching influencers at events or by providing information they can share offline is crucial, he said.

Marketers should “recognize the power of word-of-mouth and realize that it will happen whether or not a brand is involved,” said Keller. Once marketers realize the importance of word-of-mouth, they will start working with compliance experts and the FDA to make sure communications are legitimate and ethical, explained Keller, noting a similar nervousness during the early stages of DTC advertising.

Pharma companies shouldn't necessarily be worried about ceding control of the conversation to patients, since word-of-mouth among consumers tends to be far more positive than negative, according to Keller. “Sixty-nine percent of consumers–on the receiving end–find information from peers to be credible and believable, even if they aren't experts,” he said. “The [word-of-mouth] majority isn't coming from healthcare professionals.”

Keller Fay Group is a marketing research firm with a specialty in word-of-mouth research, located in New Brunswick, NJ.

Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

More in News

New lipid agents are high on potency, low on doc awareness

New lipid agents are high on potency, low ...

The new PCSK9 class of cholesterol-lowering antibodies continues to look promising, but many doctors—particularly PCPs—have never even heard of the experimental drugs.

Novartis may have game-changing drug

Novartis may have game-changing drug

Key opinion leaders indicate they are ready to embrace Novartis's experimental heart failure medication LCZ696. Such a move could upend heart failure treatment protocols.

Five things for pharma marketers to know: Tuesday, September 2

Five things for pharma marketers to know: Tuesday, ...

Sanofi and Regeneron unveil Phase-III results of their PCSK9; Merck will present data on its anti-PD-1 at the end of this month; WSJ op/ed suggests US should lead fight against ...